Current approaches to the selection of acetylsalicylic acid dosage forms in cardiology
The article is devoted to modern approaches to the selection of optimal dosage forms of acetylsalicylic acid (ASA), which ensure high bioavailability of ASA drugs. The relevance of improving the tactics of ASA use for both primary and secondary prevention of cardiovascular diseases is discussed. Cha...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«REMEDIUM GROUP» Ltd.
2022-06-01
|
| Series: | Атеротромбоз |
| Subjects: | |
| Online Access: | https://www.aterotromboz.ru/jour/article/view/267 |
| _version_ | 1797883892226588672 |
|---|---|
| author | S. R. Gilyarevskiy M. V. Golshmid N. G. Bendeliani I. M. Kuzmina |
| author_facet | S. R. Gilyarevskiy M. V. Golshmid N. G. Bendeliani I. M. Kuzmina |
| author_sort | S. R. Gilyarevskiy |
| collection | DOAJ |
| description | The article is devoted to modern approaches to the selection of optimal dosage forms of acetylsalicylic acid (ASA), which ensure high bioavailability of ASA drugs. The relevance of improving the tactics of ASA use for both primary and secondary prevention of cardiovascular diseases is discussed. Changes in the role of ASA in the prevention of cardiovascular disease complications are discussed, including as part of combined antithrombotic therapy, including ASA and either P2Y12 inhibitor or low-dose rivaroxaban. Evidence is presented that has led to doubts about the sufficient bioavailability of the enteric form of ASA, as well as the predictability of the response to therapy. A separate part of the article is devoted to the safety of different forms of ASA, in particular - the effect on the mucosa of the small intestine. The results of clinical studies evaluating the effect of ASA intake in enteric-soluble and buffered forms on the small intestinal mucosa and the risk of bleeding are presented. In addition, the problem of decreased effectiveness of ASA intake in overweight or obese individuals is considered. The article provides information on ongoing randomized trials to assess the effectiveness of increasing the frequency of ASA intake, as well as the effectiveness of chronopharmacological approaches to optimize the use of ASA. The analysis performed leads it to conclude that the buffer form can now be considered the preferred acetylsalicylic acid (ASA) dosage form, which, on the one hand, exerts a less pronounced effect on the gastric and small intestinal mucosa, and on the other hand, ensures high bioavailability, as well as minimal variability of treatment response. |
| first_indexed | 2024-04-10T03:59:01Z |
| format | Article |
| id | doaj.art-11fa64f6538e4f808cd43adf673541f0 |
| institution | Directory Open Access Journal |
| issn | 2307-1109 2658-5952 |
| language | Russian |
| last_indexed | 2024-04-10T03:59:01Z |
| publishDate | 2022-06-01 |
| publisher | «REMEDIUM GROUP» Ltd. |
| record_format | Article |
| series | Атеротромбоз |
| spelling | doaj.art-11fa64f6538e4f808cd43adf673541f02023-03-13T07:10:43Zrus«REMEDIUM GROUP» Ltd.Атеротромбоз2307-11092658-59522022-06-0112181810.21518/2307-1109-2022-12-1-8-18231Current approaches to the selection of acetylsalicylic acid dosage forms in cardiologyS. R. Gilyarevskiy0M. V. Golshmid1N. G. Bendeliani2I. M. Kuzmina3Российская медицинская академия непрерывного профессионального образованияРоссийская медицинская академия непрерывного профессионального образованияИнститут коронарной и сосудистой хирургииНаучно-исследовательский институт скорой помощи имени Н.В. СклифосовскогоThe article is devoted to modern approaches to the selection of optimal dosage forms of acetylsalicylic acid (ASA), which ensure high bioavailability of ASA drugs. The relevance of improving the tactics of ASA use for both primary and secondary prevention of cardiovascular diseases is discussed. Changes in the role of ASA in the prevention of cardiovascular disease complications are discussed, including as part of combined antithrombotic therapy, including ASA and either P2Y12 inhibitor or low-dose rivaroxaban. Evidence is presented that has led to doubts about the sufficient bioavailability of the enteric form of ASA, as well as the predictability of the response to therapy. A separate part of the article is devoted to the safety of different forms of ASA, in particular - the effect on the mucosa of the small intestine. The results of clinical studies evaluating the effect of ASA intake in enteric-soluble and buffered forms on the small intestinal mucosa and the risk of bleeding are presented. In addition, the problem of decreased effectiveness of ASA intake in overweight or obese individuals is considered. The article provides information on ongoing randomized trials to assess the effectiveness of increasing the frequency of ASA intake, as well as the effectiveness of chronopharmacological approaches to optimize the use of ASA. The analysis performed leads it to conclude that the buffer form can now be considered the preferred acetylsalicylic acid (ASA) dosage form, which, on the one hand, exerts a less pronounced effect on the gastric and small intestinal mucosa, and on the other hand, ensures high bioavailability, as well as minimal variability of treatment response.https://www.aterotromboz.ru/jour/article/view/267профилактика осложнений сердечно-сосудистых заболеванийацетилсалициловая кислотакишечнорастворимая формабуферная формабиодоступность |
| spellingShingle | S. R. Gilyarevskiy M. V. Golshmid N. G. Bendeliani I. M. Kuzmina Current approaches to the selection of acetylsalicylic acid dosage forms in cardiology Атеротромбоз профилактика осложнений сердечно-сосудистых заболеваний ацетилсалициловая кислота кишечнорастворимая форма буферная форма биодоступность |
| title | Current approaches to the selection of acetylsalicylic acid dosage forms in cardiology |
| title_full | Current approaches to the selection of acetylsalicylic acid dosage forms in cardiology |
| title_fullStr | Current approaches to the selection of acetylsalicylic acid dosage forms in cardiology |
| title_full_unstemmed | Current approaches to the selection of acetylsalicylic acid dosage forms in cardiology |
| title_short | Current approaches to the selection of acetylsalicylic acid dosage forms in cardiology |
| title_sort | current approaches to the selection of acetylsalicylic acid dosage forms in cardiology |
| topic | профилактика осложнений сердечно-сосудистых заболеваний ацетилсалициловая кислота кишечнорастворимая форма буферная форма биодоступность |
| url | https://www.aterotromboz.ru/jour/article/view/267 |
| work_keys_str_mv | AT srgilyarevskiy currentapproachestotheselectionofacetylsalicylicaciddosageformsincardiology AT mvgolshmid currentapproachestotheselectionofacetylsalicylicaciddosageformsincardiology AT ngbendeliani currentapproachestotheselectionofacetylsalicylicaciddosageformsincardiology AT imkuzmina currentapproachestotheselectionofacetylsalicylicaciddosageformsincardiology |